SciELO - Scientific Electronic Library Online

vol.55 número3Nuevas consideraciones en el tratamiento del tromboembolismo pulmonar: new considerations in its treatmentDiagnóstico de Fasciola hepatica por colangiopancreatografía retrógrada endoscópica índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO


Revista Cubana de Medicina

versão impressa ISSN 0034-7523versão On-line ISSN 1561-302X


ALFONSO FIGUEREDO, Ernesto et al. Inhibitors of dipeptidil peptidase 4 new pharmacologic strategic in the diabetes mellitus type 2. Rev cubana med [online]. 2016, vol.55, n.3, pp.239-256. ISSN 0034-7523.

Diabetes mellitus remains a fearsome disease. Proper use of pharmacotherapy for metabolic control, would help reduce the incidence of complications. Currently there are various pharmacological groups for temporary control of blood glycemia of patients with diabetes mellitus type 2. One of them is dipeptidyl peptidase-4 inhibitor characterized by stimulating increased concentration like peptide glucagon type 1 GLP -1 and insulin secretion in pancreatic islet beta cell. The effectiveness in terms of glycosylated hemoglobin has shown to be less than that of insulin, but without the potential danger of hypoglycaemia and the neutral effect or decrease in body weight. These facts prompt this literature review which was conducted to update the knowledge on the role of substances with incretin action in the metabolic control of patients with diabetes mellitus type 2, specifically the action of IDPP4, as this disease is an growing problem requiring better information on drug use.

Palavras-chave : diabetes mellitus type 2; incretins; dipeptidyl peptidase 4; glucagon-related peptide 1 (Glp-1).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons